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Abstract
Background: There have been conflicting observations regarding the receptors utilized by human multipotent
mesenchymal bone marrow stromal cells (hMSC) to adhere to endothelial cells (EC). To address the discrepancies, we
performed experiments with cells prepared with a standardized, low-density protocol preserving a sub-population of small
cells that are rapidly self-renewing.
Methods: Sialyl Lewis X (SLeX) and a4 integrin expression were determined by flow cytometry. Fucosyltransferase
expression was determined by quantitative realtime RT-PCR. Cell adhesion assays were carried out with a panel of
endothelial cells from arteries, veins and the microvasculature in vitro. In vivo experiments were performed to determine
single cell interactions in the chick embryo chorioallantoic membrane (CAM). The CAM is a well-characterized respiratory
organ allowing for time-lapse image acquisition of large numbers of cells treated with blocking antibodies against adhesion
molecules expressed on hMSC.
Results: hMSC expressed a4 integrin, SLeX and fucosyltransferase 4 and adhered to human EC from arteries, veins and the
microvasculature under static conditions in vitro. In vivo, hMSC rolled on and adhered to arterioles in the chick embryo CAM,
whereas control melanoma cells embolized. Inhibition of a4 integrin and/or SLeX with blocking antibodies reduced rolling
and adhesion in arterioles and increased embolism of hMSC.
Conclusions: The results demonstrated that rapidly self-renewing hMSC were retained in the CAM because they rolled on
and adhered to respiratory arteriolar EC in an a4 integrin- and SLeX-dependent manner. It is therefore important to select
cells based on their cell adhesion receptor profile as well as size depending on the intended target of the cell and the
injection route.
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Introduction
Human multipotent mesenchymal stromal cells, also known as
mesenchymal stem cells or hMSC, are a potentially promising
therapeutic treatment for a variety of diseases [1–3]. The cells can
differentiate into multiple cell types, but they frequently repair
tissues and prevent tissue damage without much evidence of
engraftment. Instead the repair is mediated by secretion of
paracrine factors, immunomodulation and the induction of
angiogenesis and arteriogenesis [4–9]. For many therapeutic
purposes, intravenous (IV) and intraarterial (IA) injection are the
most attractive routes of administration since the cells appear to
have the capacity to home to injured organs [10–14].
Numerous studies have demonstrated that hMSCs accumulate
in the lungs of mice following IV injection. There is still debate
whether hMSC interact with the endothelium similarly to that of
leukocytes or whether they simply become embolized in capillary
beds downstream from the injection site. The interactions of
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leukocytes with EC is a multi-step process that involves rolling and
adherence of the leukocytes followed by extravasation into
surrounding tissues (for review, see [15,16]). Ruster et al. [17]
first demonstrated that hMSC rolled and then adhered to human
umbilical vein endothelial cells (HUVEC) in a parallel plate flow
chamber. Experiments with blocking antibodies indicated that the
adherence of hMSC to HUVEC required both P-selectin and
VCAM-1/VLA-4 (a4/b1 integrin) interactions. Using intravital
microscopy of the mouse ear, they also demonstrated that hMSC
rolled on and adhered to postcapillary venules in a P-selectin
dependent manner; however, the hMSC they employed did not
express P-selectin glycoprotein ligand (PSGL). More recently, two
groups reported that hMSC did not express SLeX, a carbohydrate
component of PSGL and ligand for other selectins, in sizeable
amounts. They then demonstrated that engineering the cells to
express SLeX increased the percentage of hMSC that rolled on
activated venular endothelium in vitro and in vivo, decreased
rolling velocity and increased adherence of the cells to endothe-
lium [18,19]. In 2013, Nystedt and colleagues investigated cell
adhesion molecule involvement in lung retention of hMSC in a
mouse model. The group reported that hMSC from bone marrow
(BM-MSC) and from umbilical cord (UCB-MSC) grown at low
passage and low confluency expressed several cell adhesion
molecules. In their study, a significant percentage of UCB-MSCs
and BM-MSCs expressed SLeX, Podocalyxin-like protein 1
(PODXL1), a 6 integrin, a4 integrin and fibronectin. UCB-MSCs
expressed higher levels of alpha6 and alpha4 integrins and were
cleared from the lung more rapidly than BM-MSCs. Further,
treatment of BM-MSC and UCB-MSC with pronase to cleave
extracellular protein epitopes resulted in decreased cell signal in
the lung at 15 hours post-injection [20].
Methods to study interactions of hMSCs with endothelium of
the lung are limited due to the location of the lung within the body
and its movement [16]. The chick embryo is a unique model
system with an easily accessible external respiratory organ, the
chorioallantoic membrane (CAM). The CAM has been used
extensively to determine how cancer cells interact with the
vasculature in vivo [21–30]. The CAM and mouse lung are
characterized by similar vessel size and complexity [31]. Both
organs have a highly anastamosing system of capillaries which
creates a relatively small pressure differential across the capillary
bed in comparison to that of muscle. This smaller pressure
differential may increase the retention and survival of cancer cells
in both of these model systems [30] [32]. Additionally, the CAM
receives a large portion of the blood flow [33], allowing for the
observation of a larger number of injected cells in comparison to
the mouse ear.
In the experiments reported here, we employed hMSC grown
with a standardized protocol of low density culture that preserves a
sub-population of the cells that are rapidly self-renewing [34,35].
In contrast to preparations utilized in several earlier publications,
the hMSC expressed SLeX and a4 integrin. We first determined
the ability of the hMSC to adhere under static conditions in vitro
to EC from arterial, venous and microvascular sources and found
that hMSC preferentially adhered to unstimulated arterial EC
from two sources compared to venular endothelium and
microvascular endothelium from the dermis. We then examined
adherence and rolling of hMSC in vivo in the chick embryo CAM
because in vivo microscopy provides a unique perspective allowing
for the observation of biological phenomena in a respiratory organ
in real time under physiological conditions.
Our results indicated that hMSC had a marked tendency to
adhere to and roll on arteriolar vessels in the CAM. Rolling and
adherence to arteriolar endothelium was significantly reduced by
treatment with fucoidin, a pan-selectin inhibitor, and by injection
of blocking antibodies against SLeX and a4 integrin expressed on
the hMSC.
Materials and Methods
Ethics Statement
All animal procedures were approved by the Institutional
Animal Care and Use Committee (IACUC) at Tulane University
and conformed to the requirements of the Animal Welfare Act.
PBMC were obtained from the New Orleans Blood Center and
hMSC were obtained from the Texas A&M Institute for
Regenerative Medicine without identifiers and were therefore
IRB exempt.
Chemicals
Rhodamine Lens Culinaris Agglutinin and VectaShield with
DAPI were obtained from Vector Laboratories (Burlingame, CA).
Fluospheres, Quant-iT pico green, Cell Tracker green and Texas
Red-conjugated bovine serum albumin (BSA) were obtained from
Molecular Probes (Eugene, OR). Fucoidin was obtained from
Sigma Chemical Company (St. Louis, MO).
Preparation of Cells
Low passage number of human umbilical vein EC (HUVEC),
human iliac artery EC (HIAEC), human pulmonary artery EC
(HPAEC), human aorta EC (HAEC), human cardiac artery EC
(HCAEC) and human microvascular EC from dermis (HMVEC-
D) were obtained from Lonza, Inc. (Walkersville, MD) and
cultured in either of two commercial media (EGM2 or EGM2-
MV; Lonza). The melanoma cell line B16F1 was obtained from
the ATCC (Rockville, MD) and cultured following the recom-
mendations of the supplier.
Extensively characterized preparations of hMSC [35] were
obtained from the Texas A&M Institute for Regenerative
Medicine (http://medicine.tamhsc.edu/irm/msc-distribution.
html) and met the requirements defining multipotent mesenchy-
mal stromal cells [36]. Briefly, the cells were shown to be
multipotent for differentiation through 3 passages, were negative
for hematopoietic markers (CD34, CD36, CD117 and CD45), and
were positive for CD29 (95%), CD44 (.93%), CD49c (99%),
CD49f (.70%), CD59 (99%), CD90 (99%), CD105 (99%) and
CD166 (99%). Frozen vials containing 106 passage 1 hMSC were
plated in 150 cm2 tissue culture plates for 24 hours to recover
adherent viable cells. The cultures were washed with PBS and
adherent cells were lifted with 0.25% trypsin and 1 mM EDTA at
37 uC for 3 minutes. The cells were replated at 100 cells/cm2,
incubated for 6 to 7 days until approximately 70 to 80% confluent,
and lifted with trypsin/EDTA. For further expansion, the cells
were replated and incubated under the same conditions. The
culture medium was complete culture medium: alpha-MEM
(Gibco-BRL, Rockville, MD), 20% FBS (lot selected for rapid
growth; Atlanta Biologicals, Norcross, Ga), 1% penicillin, 100 mg/
mL streptomycin, and supplemented with 2 mM L-glutamine
(Gibco).
Static Adhesion Assay
For static adhesion assays, EC (passages 3 to 4) were grown to
confluence on 6-well collagen coated plates (BD Bioscience).
hMSC were lifted with 0.25% trypsin/1 mM EDTA and
incubated with 1 mM CellTracker Green (Molecular Probes,
Eugene, OR) according to manufacturer’s recommendation.
About 66105 hMSC were added per well to the confluent EC
at 37uC. After 15 minutes, wells were gently washed three times
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with PBS, and adherent cells were counted in 10 fields (100-fold
magnification) per well using a fluorescence camera (Zeiss) with a
software program (Metamorph Software; Molecular Devices,
Sunnyvale, CA).
Flow Cytometry
Approximately 56105 hMSC were labeled by resuspending the
cells in 500 mL PBS and incubating for 30 minutes at room
temperature (RT) with 50 mL of IgM control antibody (Zymed
Laboratories, San Fransisco, CA), 10 mL of anti-human integrin
a4-phycoerythrin (clone 9F10; BD Bioscience, San Jose, Ca),
20 mL anti-human SLeX IgM (clone CHO131) [37], or 20 mL
anti-human P-selectin IgG-FITC (clone 9E1, both from R&D
Biosystems, Minneapolis, MN). Cells were then washed three
times with 500 mL PBS and, where appropriate, incubated with
10 mL goat anti-mouse IgM AlexaFluor 488 (Invitrogen, Carlsbad,
CA) for 30 minutes. After washing three times with PBS, cells were
analyzed by flow cytometry (Cytomics FC 500; Beckman Coulter,
Fullerton, CA) with CXP software.
Real-time PCR
Total RNA was extracted from low passage, subconfluent
cultures of hMSC from 3 individual donors and from peripheral
blood mononuclear cells (PBMC) using the RNeasy Mini Kit
(Qiagen; Valencia CA). A total of 500 ng of cellular RNA was
used for cDNA synthesis using Bio-Rad iScript cDNA synthesis kit
(Bio-Rad, Hercules, CA). PCR reactions were performed using
TaqMan Universal PCR master mix (Life Technologies Applied
Biosystems, Carlsbad, CA) and the iCycler Real-Time PCR
detection system (Bio-Rad) with the following primer sets (Life
Technologies Applied Biosystems): FUT4 (Assay ID
Hs01106466_s1), FUT7 (Assay ID Hs00823637_g1), selectin P
ligand (SELPLG) (Assay ID Hs04276253_m1). Negative controls,
including cDNA reactions without reverse transcriptase or RNA
and PCR mixtures lacking cDNA were included in each PCR.
Samples amplifying at a CT value greater than 35 were considered
below the detectable range.
Embryo Injections
Fertilized white leghorn chick embryos were obtained from
Charles River Laboratories (Wilmington, MA) and stored at 4uC.
To promote development, the embryos were incubated for 11 days
at 37uC in a humidified incubator with rocking. The shell was
opened over the air pocket and the skin overlying the CAM was
rendered transparent by the addition of mineral oil. Prior to
injection, hMSC were lifted with trypsin/EDTA, washed with
PBS, counted, and re-suspended for 30 min in phenol red-free
alpha MEM without FBS but containing 10 mM CellTracker
Green for 1 hour or with 3 mL/mL PicoGreen (Molecular Probes).
The cells were isolated by centrifugation, washed with and
resuspended in phenol red-free alpha MEM. Where cells were
treated with blocking antibodies, hMSC were incubated with
50 mg/mL anti-SLeX antibody or with 5 mg/mL anti-a4 antibody
or with both antibodies (clones cho131 and 2b4, respectively;
R&D) for 1 hour at 37 uC 5% CO2. About 5610
5 hMSC, 56105,
56105 B16F1 cells or 56104 beads were resuspended in 50 mL
phenol red-free aMEM with 0.1% BSA containing 5 mL (5 mg/
mL) Texas Red BSA (Molecular Probes) to provide vessel contrast.
The egg was inverted over an inverted microscope stage, and the
cell/bead suspension was injected into a large CAM vein,
distinguished from an artery by the lighter color of the oxygenated
blood. Ten 100 ms exposure images were captured every second
for at least 3 minutes to capture velocity or every minute for 10
minutes to capture localization at 406 magnification with a
charged-coupled device camera (ORCA-ER; Hamamatsu Pho-
tonics, Bridgewater, NJ) on an inverted microscope (Eclipse
TE200; Nikon). Images were captured using Wasabi imaging
software (Hamamatsu Photonics) and later exported for analysis in
Metamorph software (Molecular Devices) or ImageJ software
(National Institutes of Health, Bethesda, Maryland). Areas
containing arteries and opposing veins separated by a capillary
bed were chosen for analysis. Vessel diameter, vessel length, cell
diameter, cell velocity (length of streak or point to point) and the
number of cells per minute were measured over 10 minutes. Vmax
was set as the speed of the fastest cell in each vessel. Cell rolling
was defined by cells moving less than the critical velocity
(Vcrit) =Vmax6(Dcell/Dvessel)/(22(Dcell/Dvessel) [38], where D is
the diameter of the cell or the vessel. Cells were counted as
adherent or embolized if they remained stationary for longer than
one frame. Cells that remained in vessels larger than their
diameter were defined as adhered to arterioles or veins whereas
cells located either in the ends of tapering arterioles or in the
capillary bed were defined as embolized. Images from at least 5
chicks were measured per condition, and all images were scored in
a blinded fashion. For 3-dimensional images, lens culinaris
agglutinin lectin conjugated with rhodamine was injected 10
minutes after injection of cells. Z-stacked images were acquired on
an upright spinning disk confocal microscope (IX70; Olympus)
using StereoInvestigator software (MBF Bioscience, Williston,
VT).
Statistical Analyses
Data are expressed +/2 SEM. ANOVAs with Tukey post-tests
and two-way ANOVAs with Bonferri post-tests were performed to
determine statistical significance (Prism 5 Software for Mac). Data
on adhesion in vitro were from experiments repeated three times
and data on observations in vivo were from experiments repeated
at least four times.
Results
hMSC adhere to EC derived from human arteries, veins
and microvasculature under static conditions in vitro
Static adhesion assays are useful tools to understand interactions
between cellular adhesion receptors and their ligands [39]. To
determine whether hMSC selectively adhere to different EC,
hMSC from two donors were added to confluent cultures of
human EC from different sources (Figure 1): HIAEC, HPAEC,
HAEC, HCAEC, HUVEC and HMVEC-D. After 15 minutes
incubation at 37 uC, unbound cells were washed away, and the
number of adherent cells per field in each well were counted using
an inverted microscope (Figure 1). hMSC preferentially adhered
to EC from the different vessels in the following order: iliac artery
(60.664.0) . pulmonary artery (37.161.9) . aorta (31.662.4) .
cardiac artery (25.262.4) $ umbilical vein (20.761.5) . dermal
microvasculature (8.760.9). The values for binding to EC from
iliac artery and pulmonary artery were significantly higher than
the values for EC from umbilical vein (p,0.001 and ,0.01
respectively) and microvasculature (p,0.001). The binding to EC
from umbilical vein was also significantly greater than to dermal
microvasculature (p,0.01). To determine whether the results
varied with different preparations of hMSC, the assays were
repeated using preparations obtained from three different donors
of bone marrow. There were no significant differences in binding
by different preparations of hMSC to EC from human iliac artery
(data not shown). These results indicated that the hMSC adhered
to all cells tested and bound preferentially to EC from two arterial
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sources compared to EC from dermal microvasculature and to EC
from human umbilical cord.
Experimental design to determine hMSC-vascular
interactions in the chick embryo CAM
To expand the in vitro observations in vivo, we used the chick
embryo CAM as described by Chambers et al. and MacDonald et
al. [28,32,40,41] (Figure 2A). In this system, arteries were defined
in time-lapse digital images as vessels in which darker blood flowed
(arrows) from larger vessels to smaller vessels and veins as vessels in
which lighter blood flowed from smaller vessels to larger vessels
(Figure 2B). We infused either hMSC or controls of B16F1
melanoma cells that were fluorescently labeled into the CAM
vasculature and obtained digital images 10 minutes later. The
results confirmed previous reports that the melanoma cells rapidly
embolized in the tapering arterioles and capillaries of the CAM
(Figure 2B. upper panel). In the process, the cells were distorted in
shape and underwent noticeable clasmatosis or membrane
blebbing. The melanoma cells did not adhere to larger vessels.
In contrast, hMSC were found primarily in arteries and arterioles
with diameters larger than the diameters of the cells (Figure 2B,
lower panel). The differences were not explained by differences in
cell size: the melanoma cells were 20.5 mm60.7 and the hMSC
19.65 mm60.6. Also in contrast to the melanoma cells, the hMSC
retained their shape without the release of vesicles that were
detectable at 1006magnification after the injection of B16F1 cells.
hMSC adhere to vessels in the chick CAM whereas
melanoma cells embolize
To confirm that hMSC adhere within large vessels in vivo, we
captured images through the z-plane of the CAM and employed
deconvolution and 3-dimension rendering to improve visualization
of cell location with respect to the vasculature. We first injected
labeled melanoma cells or hMSC into a CAM vein, and 10
minutes later injected lens culinaris agglutinin lectin conjugated
with rhodamine to improve visualization of vessels (Figure 3).
Figure 1. Low passage hMSC adhere to human arterial, venous and microvascular EC in vitro. Values are means +/2 SEM of adhered
hMSC per field (1006magnification; n = 10). Data were obtained from three experiments with hMSC from two preparations from two different donors
of marrow adhered to commercially available, pooled EC from either venous, arterial or dermal microvascular origin.
doi:10.1371/journal.pone.0105411.g001
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After 10 additional minutes, the CAM was excised and stored at
4uC until analyzed. Orthogonal projections of z-stacked images
indicated that hMSC were often found within larger vessels
beneath the capillary layer (Figure 3B), indicating that hMSC
actively adhered to endothelium of respiratory blood vessels in
vivo. In contrast, the melanoma cells were localized to the
overlying capillary plexus (Figure 3A). At this timepoint, there was
no evidence that the hMSC invaded the endothelial layer of the
vessels. (Z-stacks used to produce the orthogonal projects are
presented as Videos S1 for B16F1 and S2 for hMSC).
hMSC are cleared from the circulation more slowly than
melanoma cells or 10 mm beads. Gross inspection of time-
lapse photomicrographs suggested that hMSC persisted in the
circulation longer than melanoma cells. To examine clearance of
hMSC from the circulation of the chick embryo, we injected
hMSC and then followed their appearance in the vessels of the
CAM every minute for 10 minutes. For comparison we injected
melanoma cells or inert beads that were 10 mm in diameter under
the same conditions. Figure 4A represents total cellular flux and
figure 4B represents flux as a percentage of the total number of
Figure 2. Real time assay of cells in vessels of the chick embryo CAM. A. Schematic for injecting cells or beads into a large vein of the CAM
and capturing images for 3 to 10 minutes at either 406 or 1006magnification. B. (upper panel). Green B16F1 melanoma cells were primarily
embolized in the capillary bed and had distorted morphology (‘). (lower panel). Green hMSC retained a regular morphology and were found both
within arteries ({) and within the capillary beds (#). Images taken 10 minutes after injection of the cells. Arrows indicate direction of blood flow.
Magnification 1006.
doi:10.1371/journal.pone.0105411.g002
Figure 3. 3-Dimensional images of cells in rhodamine-labeled vesicles of chick embryo CAM. Orthologous projections of z-stacked
photomicrographs of the CAM at 2006 magnification. Crosshairs indicate cell of interest. A. B16F1 melanoma cells primarily embolized in the
overlying capillary plexus (arrowhead) and at the ends of tapering arterioles. B. An hMSC, retaining its shape, adhered in a large vessel (dashed lines)
lying beneath the capillary plexus.
doi:10.1371/journal.pone.0105411.g003
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cells or beads observed. In the first minute after the injection, a
smaller percentage of the hMSC per field were observed (20.2%
+/2 4.6; n = 7) than B16F1 melanoma cells (64.1 +/2 14.3, p,
0.001) or beads (83.0 +/2 9.6, p,0.001). By both measurements,
10 mm beads were cleared from circulation within the first minute
following bolus injection. B16F1 cells were cleared with similar
kinetics. In contrast, hMSC cellular and percentage flux per
minute was initially lower than B16F1 cells and beads and
remained higher than beads and B16F1 throughout the remaining
observation period. These data suggested that some of the hMSC
infused into veins in the CAM had circulated through the heart
and been slowed in their progress due to interactions with blood
vessels proximal to the CAM. When expressed either as cellular or
percentage flux, the data over the 10 minute interval demonstrated
that the hMSC were cleared from the circulation more slowly than
B16F1.
Low passage, rapidly dividing hMSC express SLeX and a4
integrin
Because hMSC had been previously shown to interact with
postcapillary venules in a P-selectin and VLA-4 (a4/b1 integrin)-
dependent manner [17], we analyzed low passage hMSC from
four donors to determine whether they expressed adhesion
molecules involved in this pathway. hMSC from all four donors
expressed both SLeX and a4 integrin at passage 2 (Figure 5). The
expression of both was moderately intense and expressed by nearly
100% of cells in cultures that were harvested at day 6 to 7 and 70
to 80% confluency. qRT-PCR was performed to determine
whether FUT 4 and 7, enzymes that form SLeX, were expressed
Figure 4. Clearance from the circulation of hMSC, melanoma cells and 10 mm inert beads. Inflexible inert 10 mM beads and B16F1 are
cleared from circulation faster than hMSC. A. Values for cellular flux calculated as the average number of cells or 10 mm beads counted within vessels
each minute in the CAM at 1006magnification. B. Values expressed as percentage flux were calculated as cells or beads in one minute as % of total
observed in 10 minutes (n$6).
doi:10.1371/journal.pone.0105411.g004
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in samples generated from 3 donors. FUT 4 was expressed in
samples from all 3 donors tested with average CT values of 30.8,
30.5 and 31.3 compared with an average CT value of 28.2 from
peripheral blood mononuclear cells. PSGL and FUT 7 were not
expressed.
Low passage hMSC roll on arterial EC in vivo through
SLeX and a4 integrin interactions
To define the molecules involved in the rolling and adhesion of
hMSC to vessels in vivo, we first examined the ability of fucoidin,
a pan-selectin inhibitor, to inhibit binding. After intravascular
injection of 5 mg/kg fucoidin 5 minutes prior to injection of
hMSC into the vascular system, hMSC did not appear to adhere
or roll on arteries compared with sham-injected embryos. Instead
they moved faster through the vasculature, and lodged primarily in
the capillary plexus (data not shown).
To determine which adhesion molecules were involved, we then
tested blocking antibodies against previously identified candidate
adhesion molecules. After treatment of the hMSC with anti-SLeX,
anti-a4 integrin or both antibodies together, fewer cells were seen
to adhere or roll following bolus injection suggesting that SLeX
and a4 integrin contributed to hMSC-vascular interactions. The
results were not explained by the antibodies increasing the size of
the cells, since assays of the fluorescence signal indicated that the
average diameter of hMSC was 20.360.4 mm in these experi-
ments, and the average arterial diameter was 93.564.1 mm and
was not significantly different among treatment groups. To
confirm the observations, cellular velocity was measured following
treatment with blocking antibodies (Figure 6A). Average cell
velocity increased when cells were treated with anti-a4 integrin
or SLeX antibodies, and treatment with both antibodies signifi-
cantly increased average velocity above that seen with each
antibody independently, suggesting a synergistic effect (isotype
2034.16192.7 mm/sec, a4 integrin 2074.26241.9 mm/sec, SLeX
22306231.1 mm/sec, both 2901.26258.7 mm/sec; p,0.05).
Vmax did not vary significantly among treatment conditions
(Isotype 3945.16473.0 mm/sec, a4 integrin 3114.86384.1 mm/
sec, SLeX 3298.2680.2 mm/sec, both 4371.86385.7 mm/sec)
suggesting that blood flow characteristics were not altered between
each treatment condition. When measured as a percentage of total
observed cells, 34%65 of cells treated with isotype antibodies
rolled in arteries (Figure 6B). By comparison, 9%66 of cells
treated with the a4 integrin antibody, 13%65 of cells treated with
SLeX and 15%65 of cells treated with both antibodies rolled (p,
0.05 for all values compared with isotype antibody-treated cells).
Similar results were observed when the mean number of rolling
cells was determined in arteries per millimeter of vessel. 6.7862.5
cells rolled per millimeter of artery when treated with isotype
antibody compared with 1.460.63 for SLeX antibody-treated
cells, 2.6961.92 for a4 antibody-treated cells and 1.7560.55 for
cells treated with both antibodies. Rolling velocity was significantly
higher for hMSC treated with both antibodies compared with to
hMSC treated with isotype antibody (Figure 6C). Based upon
these data, we concluded that low passage hMSC rolled in arteries
of the chick embryo CAM and that this rolling was synergistically
dependent upon interactions involving SLeX and a4 integrin
Low passage hMSC adherence in arteries is
synergistically dependent on SLeX and a4 integrin and is
not donor-dependent. To define further the roles of SLeX and
a4 integrin in vivo, we counted the number of fluorescently-
labeled cells localized within the arteries, veins and capillary bed of
the CAM three minutes after bolus injection. Cells that were
clearly localized within macrovessels larger than the diameter of
the cell were assigned to arteries or veins. Cells localized either in
the tapering ends of arterioles or within the capillary plexus were
counted as embolized. (Figure 7A) 32.3%65.0 of cells treated with
isotype antibody adhered within arteries. Treatment with both
antibodies significantly decreased arterial localization to
14.1%64.6 while the percentage of hMSC embolizing in the
capillaries or in the ends of tapering arterioles increased from
65.1%65.2 to 84.0%64.4. Treatment with anti-SLeX or anti-a4
antibody alone did not significantly decrease arterial localization
(35.4%68.5, 23.1%64.0) or increase embolism (64.3%68.7,
74.2%65.0). When the mean number of adherent cells was
determined per mm2 of the field of view for arteries, veins and
embolism at the ends of arterioles and in capillaries, the number of
embolized cells increased significantly from 4.6860.69 to
12.0863.60. Venular localization was not significantly altered by
treatment with blocking antibodies when measured as either a
percentage of total cells or as the mean number of cells per mm2.
To determine whether binding to arterial endothelium was donor
or preparation dependent, we repeated the experiment with 5
Figure 5. Low passage hMSC express a4 integrin and SLeX.
hMSC derived from four preparations from four different donors were
assayed for expression of a4 integrin and SLeX by flow cytometry.
Passage 1 cells were plated overnight to recover adherent viable cells
and then re-plated at 100 cells/cm2. The cells were harvested when 70
to 80% confluent.
doi:10.1371/journal.pone.0105411.g005
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donors and with human lymphocytes (Figure 7B). Roughly
equivalent numbers of hMSC adhered to arterial endothelium.
Thus, we concluded that the hMSC adhered to arterial EC by
synergistic binding through SLeX and a4 integrin. Of note, when
embryos were injected with confluent, high passage hMSC from
the same donors as used in the figures above, the cells formed large
aggregates and embolized in the the vessels (not shown).
Discussion
The static, in vitro assays presented in this manuscript
demonstrated that hMSC exhibit baseline adhesiveness to EC
from arteries, veins and microvasculature. In this assay hMSC
preferentially adhered to unstimulated EC from arteries compared
to EC from umbilical vein or microvasculature. The results were
extended by assays in vivo with time-lapse microscopy of the chick
embryo CAM. Experimental results obtained in the chick embryo
have been shown to be predictive of results obtained in
mammalian models [42,43]. Consistent with a previous report
by MacDonald et al, we observed that following injection into the
CAM of chick embryos, B16F1 melanoma cells failed to adhere
and embolized in small vessels [32]. In contrast to melanoma cells,
we observed a much larger fraction of hMSC in arterioles with
diameters larger than the hMSC after injection under the same
conditions. Up to 30% of low passage hMSC were found in
arterioles after intravenous injection of the cells where they were
shown to roll along the endothelium in an SLeX- and a4 integrin-
dependent manner. These results are consistent with previous
reports demonstrating that hMSC associate with arteries under
normal conditions [44–46]. In the studies presented in this
manuscript, rolling of hMSC in chick embryo venules was not
observed; however, this may be due to the experimental design.
Since the critical rolling velocity in a vessel was determined by the
fastest moving cell in that vessel, if only one or two cells passed
through a particular venule, we were unable to determine whether
the cells were rolling. Adherence, however, could be determined
by the localization of single cells. The inability of a large
percentage of injected cells to pass through the capillary plexus
has been observed in other animal models [55] and may be due to
embolism and/or adherence to the arterial or capillary vascula-
ture.
We have previously published that sub-confluent hMSC express
moderate levels of a4 and b1 integrins and that a4 integrin was the
only integrin to vary significantly based on donor preparation
[47,48]. Subtle variations in the properties of different prepara-
tions of hMSC may have important implications for therapeutic
uses of the cells. For example, the tendency of hMSC to form
lethal pulmonary emboli in mice was shown to vary with different
protocols for preparing the cells that altered the expression of anti-
cell adhesion surface proteins such as podocalyxin-like protein
[49].
The chick embryo CAM can readily be visualized and has been
used extensively to determine how cancer cells interact with the
vasculature in vivo [21–30]. The CAM receives a large portion of
the total blood flow in the egg [33], allowing for the observation of
a larger fraction of injected cells than either the mouse ear or
mesentery. Circulating cells in chick blood express selectin ligands
including SLeX carbohydrate moieties and integrins, and chick
embryo endothelium expresses appropriate binding partners for
these molecules including selectins, VCAM-1 and fibronectin
necessary for homing[27,50–54].
Similar to the experimental results of Ruster et al., we found
that genetically and biochemically unmodified hMSC were
capable of rolling on and adhering to endothelium [17]. The
results presented here differ however in that Ruster et al. focused
on venous EC (HUVEC) and post-capillary venules. Our results
also differ from the results of several studies in which hMSC were
found not to express SLeX and that fewer than 50% hMSC
expressed a4-integrin [17–19,56]. These differences may be
Figure 6. Effects of anti-SLeX and anti-a4 integrin on MSC
rolling on arterial endothelium in vivo. A. Per cent of hMSC rolling
without or with pre-treatment with anti-SLeX, anti-VL a4 integrin, or
both antibodies. * = p,0.05 B. Average velocity of the cells. Vmax did
not significantly change among treatment conditions (avera-
ge = 3682.4629.1 mm/sec). Measuring fluorescence signal, DhMSC was
20.360.4 mm in these experiments. Dartery was 93.564.1 mm and was
not significantly different among treatment groups. * = p,0.05. C.
Rolling velocities of the cells. * p,0.01.
doi:10.1371/journal.pone.0105411.g006
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explained by their use of high passage (up to passage 20) cultures
instead of the early passage (2–3) and low density cultures used
here that are enriched for smaller and rapidly-replicating hMSC
[34,35]. In support of this assertion, Greenberg et al. demonstrat-
ed that the most naive CD34+ hematopoetic stem cells rolled
avidly in a PSGL-dependent manner in a flow chamber on
immobilized P-selectin and that their ability to roll and adhere
decreased as the cells differentiated [57]. Additionally, we
observed that when hMSC obtained from confluent, high passage
cultures were injected into the chick embryo, the cells aggregated
and formed emboli that occluded larger vessels (unpublished data).
Similarly to Nystedt and Kerkela, we found that hMSC from bone
marrow utilize a4 integrin for adhesion to respiratory endotheli-
um. In the CAM model system, SLeX and a4 integrin were both
involved in hMSC rolling and adherence whereas the contribution
played by SLeX was not apparent in the mouse lung [20,58].
Additional experiments will be necessary to determine whether
SLeX and a4 integrin are the primary adhesion molecules utilized
by hMSC in various disease states and in different organs.
Many observations support the association of MSC with arteries
[44]. The results presented in this manuscript are in agreement
with studies in mice showing that murine MSC home to
perivascular sites and contribute to arteriogenesis and decrease
arterial resistance [6]. Murine MSC deficient in apolipoprotein E
(ApoE) incorporate into the aorta and reduce angiotensin II-
induced aortic aneurysm formation in ApoE-deficient mice [59].
We have also observed that hMSC and to a greater degree, serum-
deprived hMSC are highly angiogenic and incorporate into the
vasculature of the chick embryo CAM [9].
Although lung adherence by MSCs is generally considered a
negative consequence of IV injection, several major diseases
involve inflammation of the lung including interstitial lung disease,
asthma, emphysema, chronic obstructive pulmonary disorder,
cystic fibrosis and acute respiratory distress syndrome. In these
Figure 7. Distribution of hMSC to arteries/arterioles, veins and capillaries/end arterioles in the CAM. A. Distribution of hMSC compared
to lymphocytes and effects of pre-treatment with anti-SLeX and/or anti-a4 integrin (n = 5). B. Distribution in arteries of hMSC from 5 preparations
from 5 different donors of marrow repeated 5 times.
doi:10.1371/journal.pone.0105411.g007
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cases, increased concentration of the cells following IV injection
would presumably be beneficial due to their immunosuppressive
characteristics and thus warrants further study; however,
PODXL1, a6 integrin and other cell adhesion molecules should
be examined both individually and in combination.
Supporting Information
Video S1 Videos were compiled from z stack images at
2006magnification displaying B16F1 cells and hMSC in
large vessels and in the overlying capillary plexus. Vessels
were counterstained after cell injection by lens culinaris agglutinin
rhodamine injection. Images were acquired on a spinning disk
confocal microscope using StereoInvestigator software. (S1) B16F1
cells were found primarily in the overlying capillary plexus. (S2)
hMSC located beneath the capillary plexus in a larger vessel.
(MP4)
Video S2 Videos were compiled from z stack images at
2006magnification displaying B16F1 cells and hMSC in
large vessels and in the overlying capillary plexus. Vessels
were counterstained after cell injection by lens culinaris agglutinin
rhodamine injection. Images were acquired on a spinning disk
confocal microscope using StereoInvestigator software. (S1) B16F1
cells were found primarily in the overlying capillary plexus. (S2)
hMSC located beneath the capillary plexus in a larger vessel.
(MP4)
Video S3 Video was compiled from time-lapse images
taken every second at 1006magnification. Green hMSC
treated with isotype control antibody can be seen free-flowing or
rolling in an artery contrasted with Texas Red BSA.
(MP4)
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